Small Pharma’s SPL026 Phase IIa trial results update – George Tziras, CEO

Small Pharma’s CEO George Tziras shares his thoughts on the impact of our Phase IIa trial investigating SPL026 in Major Depressive Disorder, and what the results could mean for the future of patient care.

About Small Pharma

We’re a biotechnology company researching and developing short-acting psychedelics with supportive therapy for mental health conditions.

Register for Company Updates

    Corporate Presentation

    Follow us: